Opinion

Video

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

Author(s):

Elizabeth R. Plimack, MD, MS, FASCO,Neeraj Agarwal, MD

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Related Videos
Neil Iyengar, MD, and Chandler Park, MD, FACP
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Tiago Biachi, MD, PhD
Related Content
Multiple Myeloma | stock.adobe.com
December 19th 2024

New Protocol Reduces Adverse Effects In Use of Key Drug for Multiple Myeloma

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Fellows of the American College of Surgeons | Image Credit: © Katsyarina - stock.adobe.com
December 4th 2024

Fox Chase Cancer Center’s Dr. Anthony M. Villano and Dr. Austin D. Williams Named Fellows of the American College of Surgeons

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

ALLO-316 in Advanced CD70-Positive ccRCC | Image Credit: © Cornflakesei - stock.adobe.com
November 27th 2024

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

Chelsey Schlechter, MPH, PhD
November 27th 2024

Dr Schlechter Named Cancer Moonshot Scholar